Cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease in the UK (2012) Yang Meng Hazel Squires John Stevens Emma Simpson Steve Thomas Jonathan Michaels Gerard Stansby Mark O'Donnell 10.15131/shef.data.11913492.v1 https://orda.shef.ac.uk/articles/poster/Cost-effectiveness_of_cilostazol_naftidrofuryl_oxalate_pentoxifylline_and_inositol_nicotinate_for_the_treatment_of_intermittent_claudication_in_people_with_peripheral_arterial_disease_in_the_UK_2012_/11913492 <p>The study aims to assess the cost-effectiveness of the vasoactive drugs cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conservative management.</p> <br> 2020-02-28 11:41:42 peripheral arterial disease cilostazol naftidrofuryl oxalate inositol nicotinate Health Economics